Kadmon Holdings, Inc.:
Late-stage biotech developing small molecules and biologics; focused on inflammation, fibrosis and I-O. Lead candidate KD025 is a ROCK2 inhibitor in a registration trial cGVHD. Platform of ROCK inhibitors for fibrotic diseases. Also developing IL-15-contaning fusion proteins for I-O.
450 East 29th Street
New York, NY 10016
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by